Comparison of Magnetic Resonance Imaging T2 Results in Beta-Thalassemia Patients Treated by Deferasirox or Combination of Deferoxamine and Deferiprone

IF 0.4 Q4 PEDIATRICS
N. Mirbehbahani, G. Vaseghi, A. Rashidbaghan, M. Vakili, A. Jahazi
{"title":"Comparison of Magnetic Resonance Imaging T2 Results in Beta-Thalassemia Patients Treated by Deferasirox or Combination of Deferoxamine and Deferiprone","authors":"N. Mirbehbahani, G. Vaseghi, A. Rashidbaghan, M. Vakili, A. Jahazi","doi":"10.18502/ijpho.v10i4.4407","DOIUrl":null,"url":null,"abstract":"Background: Iron extra load is an anticipated and lethal consequence of chronic blood transfusion in major beta-thalassemia patients; therefore it is necessary to use an efficient iron chelator drug to stimulate the evacuation of the surplus iron from the body. This trial was performed to compare myocardial and hepatic magnetic resonance imaging T2 (MRI T2*) results of beta-thalassemia patients treated by Deferasirox or combination of Deferoxamine and Deferiprone. Material and Methods: In this clinical trial, 44 patients who were on combination therapy with Deferiprone and Deferoxamine and complied with the inclusion criteria were randomized to either case (Deferasirox) or control (combined therapy) groups. Twenty-two patients in the case group received Deferasirox. For 22 patients in the control group, prior treatment with Deferiprone and Deferoxamine was continued. Myocardial and hepatic MRI T2* results were assessed before and after the study. Moreover, serum ferritin level (SFL) was evaluated every 3 months. Results: SFL at the start of the study did not differ significantly in two groups (2158.1± 1012.2 μg/L in the control group vs. 2145.5±1121.4 μg/L in the case group) (P=0.08). SFL at the end of the study did not differ significantly in two groups (2204.4±1143.5 μg/L in the control group vs. 2347.2±1236.6 μg/L in the case group), either (P=0.12). In each group, myocardial and hepatic MRI T2 at the start and at the end of the trial did not differ significantly (P>0.1). Conclusion: Myocardial and hepatic MRI T2*results were better in the control (combination therapy) group than those in the case (Deferasirox) group. Major beta-thalassemia patients replied to combined treatment better than Deferasirox.","PeriodicalId":44212,"journal":{"name":"Iranian Journal of Pediatric Hematology and Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2020-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Pediatric Hematology and Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/ijpho.v10i4.4407","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Iron extra load is an anticipated and lethal consequence of chronic blood transfusion in major beta-thalassemia patients; therefore it is necessary to use an efficient iron chelator drug to stimulate the evacuation of the surplus iron from the body. This trial was performed to compare myocardial and hepatic magnetic resonance imaging T2 (MRI T2*) results of beta-thalassemia patients treated by Deferasirox or combination of Deferoxamine and Deferiprone. Material and Methods: In this clinical trial, 44 patients who were on combination therapy with Deferiprone and Deferoxamine and complied with the inclusion criteria were randomized to either case (Deferasirox) or control (combined therapy) groups. Twenty-two patients in the case group received Deferasirox. For 22 patients in the control group, prior treatment with Deferiprone and Deferoxamine was continued. Myocardial and hepatic MRI T2* results were assessed before and after the study. Moreover, serum ferritin level (SFL) was evaluated every 3 months. Results: SFL at the start of the study did not differ significantly in two groups (2158.1± 1012.2 μg/L in the control group vs. 2145.5±1121.4 μg/L in the case group) (P=0.08). SFL at the end of the study did not differ significantly in two groups (2204.4±1143.5 μg/L in the control group vs. 2347.2±1236.6 μg/L in the case group), either (P=0.12). In each group, myocardial and hepatic MRI T2 at the start and at the end of the trial did not differ significantly (P>0.1). Conclusion: Myocardial and hepatic MRI T2*results were better in the control (combination therapy) group than those in the case (Deferasirox) group. Major beta-thalassemia patients replied to combined treatment better than Deferasirox.
去铁胺与去铁胺与去铁素联合治疗β -地中海贫血患者的磁共振成像T2结果比较
背景:铁额外负荷是主要β地中海贫血患者长期输血的预期和致命后果;因此,有必要使用有效的铁螯合剂药物来刺激多余的铁从体内排出。本试验旨在比较接受去甲罗克斯或去甲罗胺和去甲酮联合治疗的β地中海贫血患者的心肌和肝脏磁共振成像T2(MRI T2*)结果。材料和方法:在本临床试验中,44名接受去铁酮和去铁胺联合治疗并符合纳入标准的患者被随机分为病例组(去铁罗克斯)或对照组(联合治疗)。病例组中有22名患者接受了去甲罗司。对照组中的22名患者继续先前的去铁酮和去铁胺治疗。在研究前后评估心肌和肝脏MRI T2*结果。此外,每3个月对血清铁蛋白水平(SFL)进行一次评估。结果:两组在研究开始时的SFL没有显著差异(对照组2158.1±1012.2μg/L与病例组2145.5±1121.4μg/L)(P=0.08)。研究结束时,两组的SFL也没有显著差异,对照组为2204.4±1143.5μg/L,病例组为2347.2±1236.6μg/L(P=0.012),心肌和肝脏MRI T2 结论:对照组(联合治疗)的心肌和肝脏MRI T2*结果优于病例组(去甲罗司)。主要β地中海贫血患者对联合治疗的反应好于去甲罗司。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.80
自引率
33.30%
发文量
33
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信